By Mike Ward
Editor, Europe

OXFORD - Elliot Goldstein, the new CEO at British Biotech plc, has wasted no time stamping his mark on the company. Within six weeks of taking up arguably the most challenging job in European biotech, Goldstein has wiped away more than 10 years of corporate ambition by abandoning the fully integrated pharmaceutical company (FIPCO) business model for a more conservative partnering strategy.